Now, a series of clinical trials from a team of international researchers suggests a new medication called atogepant may offer something previously elusive in migraine prevention: rapid relief ...

Qulipta (atogepant) is FDA approved for both chronic and episodic migraine prevention in adults. Ongoing data shows safety and promising results in patients who've failed multiple other preventives.

AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine in the EU as it tries to catch up with main rivals Pfizer/BioHaven and their recently ...